Instem and Sable Bio Launch Partnership to Accelerate Target Risk Assessment Through AI-Powered Scientific Intelligence

Drug-discovery software provider Instem and biotechnology company Sable Bio announced a partnership to add Sable Bio’s Target Intelligence platform to Instem’s KnowledgeScan service. The cloud-based offering combines AI-assisted scientific literature analysis with expert review to help biopharmaceutical researchers assess target safety and identify potential risks earlier. The companies say the service is available immediately and is intended to speed research and support development decisions. Business Wire carried the announcement.